Literature DB >> 15354862

Osteoblastic cells express phospholipid receptors and phosphatases and proliferate in response to sphingosine-1-phosphate.

A Grey1, X Xu, B Hill, M Watson, K Callon, I R Reid, J Cornish.   

Abstract

Sphingosine-1-phosphate (S1P) is a naturally occurring polar phospholipid that exerts growth-factor--like effects in a number of cell types, potentially by endocrine, paracrine, and intracrine mechanisms. The biological actions of S1P are mediated in part by its specific binding to at least four members of the edg/lp family of G protein-coupled receptors (edg 1, 3, 6, and 8), and further regulated by the actions of specific cell membrane-bound lipid phosphate phosphatases (LPPs). Recent evidence has suggested that S1P may act as an osteoblast growth factor. In the current study, we demonstrate expression in osteoblastic cells of the S1P receptors edg 1, edg 5 and edg 8; the lipid phosphate phosphatases LPP-1, LPP-2, and LPP-3, and the S1P phosphatase mSPP1. S1P exerts dose-dependent mitogenic effects in cultures of primary rat osteoblastic cells and SaOS-2 cells. S1P also activates p42/44 mitogen-activated protein (MAP) kinases in osteoblastic cells, and the proliferative effects of S1P in these cultures are partially abrogated by PD-98059 and U-0126, specific inhibitors of p42/44 MAP kinase signaling. S1P-induced p42/44 MAP kinase activation in osteoblastic cells is dependent on functional Gi proteins and intracellular calcium fluxes, but not on protein kinase A, phospha-tidylinositol-3 kinase, or protein Kinase C. These data demonstrate (1) the expression by osteoblastic cells of several cell membrane-bound components of phospholipid signaling and (2) that S1P is a potent osteoblast mitogen, the proliferative action of which is mediated by a signaling pathway that involves Gi proteins, intracellular calcium, and p42/44 MAP kinases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15354862     DOI: 10.1007/s00223-003-0155-9

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  20 in total

1.  FTY720 promotes local microvascular network formation and regeneration of cranial bone defects.

Authors:  Caren E Petrie Aronin; Lauren S Sefcik; Sunil S Tholpady; Ashok Tholpady; Karim W Sadik; Timothy L Macdonald; Shayn M Peirce; Brian R Wamhoff; Kevin R Lynch; Roy C Ogle; Edward A Botchwey
Journal:  Tissue Eng Part A       Date:  2010-06       Impact factor: 3.845

Review 2.  Coupling factors involved in preserving bone balance.

Authors:  Beom-Jun Kim; Jung-Min Koh
Journal:  Cell Mol Life Sci       Date:  2018-12-04       Impact factor: 9.261

Review 3.  Lysophosphatidic Acid and Sphingosine-1-Phosphate: A Concise Review of Biological Function and Applications for Tissue Engineering.

Authors:  Bernard Y K Binder; Priscilla A Williams; Eduardo A Silva; J Kent Leach
Journal:  Tissue Eng Part B Rev       Date:  2015-07-14       Impact factor: 6.389

Review 4.  The Utility of Biomarkers in Osteoporosis Management.

Authors:  Patrick Garnero
Journal:  Mol Diagn Ther       Date:  2017-08       Impact factor: 4.074

5.  The circulating sphingosine-1-phosphate level predicts incident fracture in postmenopausal women: a 3.5-year follow-up observation study.

Authors:  S J Bae; S H Lee; S H Ahn; H-M Kim; B-J Kim; J-M Koh
Journal:  Osteoporos Int       Date:  2016-03-16       Impact factor: 4.507

Review 6.  Sphingosine 1-phosphate (S1P) signalling: Role in bone biology and potential therapeutic target for bone repair.

Authors:  Ziad Sartawi; Ernestina Schipani; Katie B Ryan; Christian Waeber
Journal:  Pharmacol Res       Date:  2017-09-22       Impact factor: 7.658

7.  The effect of sphingosine-1-phosphate on bone metabolism in humans depends on its plasma/bone marrow gradient.

Authors:  B-J Kim; K-O Shin; H Kim; S H Ahn; S H Lee; C-H Seo; S-E Byun; J S Chang; J-M Koh; Y-M Lee
Journal:  J Endocrinol Invest       Date:  2015-07-29       Impact factor: 4.256

8.  Sustained release of sphingosine 1-phosphate for therapeutic arteriogenesis and bone tissue engineering.

Authors:  Lauren S Sefcik; Caren E Petrie Aronin; Kristen A Wieghaus; Edward A Botchwey
Journal:  Biomaterials       Date:  2008-04-11       Impact factor: 12.479

9.  Absence of the lysophosphatidic acid receptor LPA1 results in abnormal bone development and decreased bone mass.

Authors:  Isabelle Gennero; Sara Laurencin-Dalicieux; Françoise Conte-Auriol; Fabienne Briand-Mésange; Danielle Laurencin; Jackie Rue; Nicolas Beton; Nicole Malet; Marianne Mus; Akira Tokumura; Philippe Bourin; Laurence Vico; Gérard Brunel; Richard O C Oreffo; Jerold Chun; Jean Pierre Salles
Journal:  Bone       Date:  2011-05-01       Impact factor: 4.398

Review 10.  Animal models of osteogenesis imperfecta and related syndromes.

Authors:  Agnès S Kamoun-Goldrat; Martine F Le Merrer
Journal:  J Bone Miner Metab       Date:  2007-06-25       Impact factor: 2.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.